Minocycline hydrochloride nanoliposomes inhibit the production of TNF-α in LPS-stimulated macrophages

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4769-4775

  Liu, D ^a   Yang, P S ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Lipopolysaccharide; Macrophages; Minocycline hydrochloride; Nanoliposomes; Periodontitis; Tumor necrosis factor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; LIPOPOLYSACCHARIDE; LIPOSOME; MESSENGER RNA; MINOCYCLINE; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; GENE; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR ALPHA GENE;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; LIPOPOLYSACCHARIDES; LIPOSOMES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MINOCYCLINE; NANOCAPSULES; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 84870309526     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34036     Document Type: Article

References (35)

1. Socransky S, Haffajee A. Evidence of bacterial aetiology: a historical perspective. Periodontol 2000. 1994;5:7-25.
2. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4:1-6.
3. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, etal. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2004;24:2174-2180.
4. Li L, Khansari A, Shapira L, etal. Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo. Infect Immun. 2002;70:3915-3922.
5. Chiang CY, Kyritsis G, Graves DT, etal. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun. 1999;67: 4231-4236.
6. Page RC. The microbiological case for adjunctive therapy for periodontitis. J Int Acad Periodontol. 2004;6:143-149.
7. Zhao N, Ge SH, Ding GY. Clinical effect of minocycline as adjunctive therapy to scaling and root planning on treatment of chronic Hua Xi Kou Qiang Yi Xue Za Zhi. 2006;24:32-35.
8. Cortelli JR, Querido SM, Aquino DR, etal. Longitudinal clinical evaluation of adjunct minocycline in the treatment of chronic J Periodontol. 2006;77:161-166.
9. Paquette DW, Ryan ME, Wilder RS. Locally delivered antimicrobials: clinical evidence and relevance. J Dent Hyg. 2008;3:10-15.
10. Gopinath V, Ramakrishnan T, Emmadi P, etal. Effect of a controlled release device containing minocycline microspheres on the treatment of chronic periodontitis: A comparative study. J Indian Soc Periodontol. 2009;13:79-84.
11. Suntres ZE, Shek PN. Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem Pharmacol. 2000;59:1155-1161.
12. Ratnam DV. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J Control Release. 2006;113:189-207.
13. Osawa M, Anderson DE, Erickson HP. Reconstitution of contractile FtsZ Rings in liposomes. Science. 2008;9:792-794.
14. Pascale D, Gordon I, Lamster I, etal. Concentration of doxycycline in human gingival fluid. J Clin Periodontol. 1986;13:841-844.
15. Walters JD, Nakkula RJ, Maney P. Modulation of gingival fibroblast minocycline accumulation by biological mediators. J Dent Res. 2005;84:320-323.
16. Park SY, Park DJ, Kim YH, etal. Schisandra chinensis α-iso-cubebenol induces heme oxygenase-1 expression through PI3K/Akt and Nrf2signaling and has anti-inflammatory activity in Porphyromonas gingivalis lipopolysaccharide-stimulated macrophages. Int Immunopharmacol. 2011;11:1907-1915.
17. Larsen T. Occurrence of doxycycline resistant bacteria in the oral cavity after local administration of doxycycline in patients with periodontal disease. Scand J Infect Dis. 1991;23:89-95.
18. Roberts FA, Hockett RD, Bucy RP, etal. Quantitative assessment of inflammatory cytokine gene expression in chronic adult periodontitis. Oral Microbiol Immunol. 1997;12:336-344.
19. Gamonal J, Acevedo A, Bascones A, etal. Levels of interleukin-1 beta,-8, and-10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol. 2000;71:1535-1545.
20. Thammasitboon K, Goldring SR, Boch JA. Role of macrophages in LPS-induced osteoblast and PDL cell apoptosis. Bone. 2006;38: 845-852.
21. Kumada H, Haishima Y, Umemoto T, etal. Structural study on the free lipid A isolated from lipopolysaccharide of Porphyromonas gingivalis. J Bacteriol. 1995;177:2098-2106.
22. Yoshimura A, Hara Y, Kaneko T, etal. Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1 alpha by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res. 1997;32:279-286.
23. Vandekerckhove BN, Quirynen M, van Steenberghe D. The use of locally-delivered minocycline in the treatment of chronic periodontitis. A review of the literature. J Clin Periodontol. 1998;25:964-968.
24. Zink MC, Uhrlaub J, DeWitt J, etal. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293: 2003-2011.
25. Que RP, Liu XF, Qian QF, etal. A clinical study of periocline on the treatment of severe chronic periodontitis. Shanghai Kou Qiang Yi Xue. 2005;14:257-259.
26. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
27. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297-305.
28. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Ann Rev Anal Chem. 2008;1:801-832.
29. Basha G, Nonobrantseva TI, Rosin N, etal. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011;19: 2186-2200.
30. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. J Membrane Sci. 1997;127:223-227.
31. Mandal TK. Swelling-controlled release system for the vagina delivery of miconazole. Eur J Pharm Biopharm. 2000;50:337-343.
32. Jantzen GM, Robinson JR. Sustained and controlled-release drug delivery systems. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. New York, NY: Marcel Dekker, Inc; 2002:501-528.
33. Lu Z, Chen W, Hamman JH. Chitosan-polycarbophil interpolyelectrolyte complex as a matrix former for controlled release of poorly water-soluble drugs I: in vitro evaluation. Drug Dev Ind Pharm. 2010;36: 539-546.
34. Matsuo H, Wakasugi M, Takanaga H, etal. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J Control Release. 2011;77:77-86.
35. Nobili S, Landini I, Giglioni B, etal. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7: 861-879.